Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.
The Company's lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. The Company has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. The Company is conducting a double-blinded, randomized Phase II trial at over six sites in the United States. The Company has initiated approximately two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK lesions on the face, trunk and extremities. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts.
The Company has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, for specified dermatological conditions. The Company focuses on developing these JAK inhibitors, A-201 and A-301, as treatments for hair loss associated with an autoimmune skin disease known as alopecia areata (AA), and for other dermatological conditions. The Company focuses on developing A-201 as an oral treatment for alopecia totalis and alopecia universalis and A-301 as a topical treatment for patchy AA.
101 Lindenwood Dr Ste 400
The company trades on NASDAQ exchange. The company headquarter is located in Pennsylvania, PA. The company was established in the 2012.| Ticker | ACRS |
| Long Name | Aclaris Therapeutics, Inc. |
| Short Name | Aclaris Therapeutics |